Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, we bring together physicians, scientists, and patients to devise new and powerful approaches to patient care. Our company engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. We are a family-owned business with a global presence, we have ten affiliates in Europe and Australia and are continuously growing. Our company has its headquarters and R&D facilities in Freiburg, Germany, and our pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, and Switzerland. Dr. Falk Pharma GmbH employs approximately 990 individuals globally, of those 218 in Freiburg. Imprint: https://drfalkpharma.com/en/imprint/ Social Media Guidelines: https://drfalkpharma.com/en/social-media-guidelines/